ArticleJournal for immunotherapy of cancer2022

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.

Won Suk Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.